JP2002505323A - インテグリンアンタゴニストであるメタ‐アザサイクリックアミノ安息香酸化合物類及びその誘導体 - Google Patents

インテグリンアンタゴニストであるメタ‐アザサイクリックアミノ安息香酸化合物類及びその誘導体

Info

Publication number
JP2002505323A
JP2002505323A JP2000534538A JP2000534538A JP2002505323A JP 2002505323 A JP2002505323 A JP 2002505323A JP 2000534538 A JP2000534538 A JP 2000534538A JP 2000534538 A JP2000534538 A JP 2000534538A JP 2002505323 A JP2002505323 A JP 2002505323A
Authority
JP
Japan
Prior art keywords
embedded image
added
condition
treated
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000534538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002505323A5 (zh
Inventor
ロジャーズ，トーマス，イー
ルミンスキー，ピーター，ジー
Original Assignee
ジー・ディー・サール・アンド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジー・ディー・サール・アンド・カンパニー filed Critical ジー・ディー・サール・アンド・カンパニー
Publication of JP2002505323A publication Critical patent/JP2002505323A/ja
Publication of JP2002505323A5 publication Critical patent/JP2002505323A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000534538A 1998-03-04 1999-02-22 インテグリンアンタゴニストであるメタ‐アザサイクリックアミノ安息香酸化合物類及びその誘導体 Pending JP2002505323A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3427098A 1998-03-04 1998-03-04
US09/034,270 1998-03-04
PCT/US1999/003281 WO1999044994A1 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists

Publications (2)

Publication Number Publication Date
JP2002505323A true JP2002505323A (ja) 2002-02-19
JP2002505323A5 JP2002505323A5 (zh) 2005-08-18

Family

ID=21875345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000534538A Pending JP2002505323A (ja) 1998-03-04 1999-02-22 インテグリンアンタゴニストであるメタ‐アザサイクリックアミノ安息香酸化合物類及びその誘導体

Country Status (29)

Country Link
EP (1) EP1060164A1 (zh)
JP (1) JP2002505323A (zh)
KR (1) KR20010041584A (zh)
CN (1) CN1214011C (zh)
AP (1) AP1244A (zh)
AR (1) AR018139A1 (zh)
AU (1) AU753230B2 (zh)
BG (1) BG104740A (zh)
BR (1) BR9908470A (zh)
CA (1) CA2322207A1 (zh)
EA (1) EA200000804A1 (zh)
EE (1) EE200000506A (zh)
GE (1) GEP20033118B (zh)
HR (1) HRP20000574A2 (zh)
HU (1) HUP0100865A3 (zh)
ID (1) ID25591A (zh)
IL (1) IL137653A0 (zh)
IS (1) IS5582A (zh)
MY (1) MY123908A (zh)
NO (1) NO315703B1 (zh)
NZ (1) NZ506598A (zh)
OA (1) OA11530A (zh)
PL (1) PL342726A1 (zh)
SK (1) SK13002000A3 (zh)
TR (1) TR200002542T2 (zh)
UA (1) UA71906C2 (zh)
WO (1) WO1999044994A1 (zh)
YU (1) YU52000A (zh)
ZA (1) ZA994406B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4792124B1 (ja) * 2010-11-15 2011-10-12 エフイートレード株式会社 車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
AU2003299600A1 (en) * 2002-12-20 2004-07-29 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
JP2010520238A (ja) 2007-03-01 2010-06-10 マリンクロット インコーポレイテッド 統合された光活性低分子および統合された光活性低分子使用
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CA2878469A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
EP3151670B1 (en) * 2014-06-04 2019-10-02 Monsanto Technology LLC 3,6-dichlorosalicylic acid compounds and related synthetic processes
ES2806276T3 (es) 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
JPWO2021230325A1 (zh) 2020-05-14 2021-11-18
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2230209A1 (en) * 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4792124B1 (ja) * 2010-11-15 2011-10-12 エフイートレード株式会社 車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法

Also Published As

Publication number Publication date
NO315703B1 (no) 2003-10-13
NO20004316L (no) 2000-11-06
TR200002542T2 (tr) 2001-05-21
EE200000506A (et) 2002-04-15
KR20010041584A (ko) 2001-05-25
MY123908A (en) 2006-06-30
HUP0100865A2 (hu) 2001-08-28
NZ506598A (en) 2003-07-25
IS5582A (is) 2000-08-04
CN1214011C (zh) 2005-08-10
SK13002000A3 (sk) 2001-07-10
AR018139A1 (es) 2001-10-31
ID25591A (id) 2000-10-19
BG104740A (en) 2001-02-28
IL137653A0 (en) 2001-10-31
WO1999044994A1 (en) 1999-09-10
AU3294799A (en) 1999-09-20
HRP20000574A2 (en) 2001-08-31
AU753230B2 (en) 2002-10-10
GEP20033118B (en) 2003-11-25
EA200000804A1 (ru) 2001-04-23
NO20004316D0 (no) 2000-08-30
ZA994406B (en) 2000-02-11
CA2322207A1 (en) 1999-09-10
EP1060164A1 (en) 2000-12-20
BR9908470A (pt) 2000-12-05
AP1244A (en) 2004-02-04
HUP0100865A3 (en) 2001-11-28
AP2000001893A0 (en) 2000-09-30
PL342726A1 (en) 2001-07-02
CN1291978A (zh) 2001-04-18
UA71906C2 (en) 2005-01-17
OA11530A (en) 2004-05-17
YU52000A (sh) 2003-02-28

Similar Documents

Publication Publication Date Title
JP2002505323A (ja) インテグリンアンタゴニストであるメタ‐アザサイクリックアミノ安息香酸化合物類及びその誘導体
AU765294B2 (en) Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
JP2000510098A (ja) 桂皮酸誘導体
JP2000515493A (ja) パラ―置換フェニレン誘導体
JPH11510814A (ja) インテグリンアンタゴニストとしてのメタ−グアニジン、尿素、チオ尿素またはアザ環状アミノ安息香酸誘導体
US6372719B1 (en) ανβ3 integrin antagonists in combination with chemotherapeutic agents
PT889875E (pt) Derivados de acidos ciclopropilalcanoicos
JP2002501054A (ja) 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体
MXPA05006732A (es) El isomero r de compuesto de beta-aminoacido como derivados de antagonistas de receptor de la integrina.
US6013651A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof
US5798370A (en) Platelet aggregation inhibitors
US6100423A (en) Amino benzenepropanoic acid compounds and derivatives thereof
WO2000032578A1 (en) Benzimidazole compounds that are vitronectin receptor antagonists
US5681820A (en) Guanidinoalkyl glycine β-amino acids useful for inhibiting tumor metastasis
CZ20011963A3 (cs) Antagonista vitronektinového receptoru
US6172256B1 (en) Chiral-β-amino acid compounds and derivatives thereof
US6689754B1 (en) Heterocyclic glycyl β-alanine derivatives
MXPA00008427A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
CZ20003218A3 (cs) Deriváty meta-azacyklické aminobenzoové kyseliny a jejich deriváty, které jsou antagonisty integrinu
MXPA01005395A (en) Benzimidazole compounds that are vitronectin receptor antagonists

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080115